Compound

Orforglipron

2 sourced research updates tagged Orforglipron, newest first — what changed, what the evidence shows and what it means for how people run a protocol.

GLP-1 & metabolic2026-08-10

The first small-molecule GLP-1 pill is approved — what Foundayo changes

In April 2026 the FDA approved orforglipron (brand name Foundayo), the first small-molecule oral GLP-1 receptor agonist for chronic weight management.

Orforglipron Semaglutide GLP-1 receptor agonist Small molecule FDA approved

GLP-1 & metabolic2026-08-05

When will orforglipron actually be available to fill at a pharmacy?

Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist that has completed its Phase 3 ATTAIN and ACHIEVE programs and is under regulatory review.

Orforglipron GLP-1 receptor agonist Phase 3

All research updates

Who maintains this page

The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine. We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.

Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.

Cite DoseRoutine

Quoting or summarizing this page? Please credit DoseRoutine and link back.

DoseRoutine — DoseRoutine. https://doseroutine.com/blog/tag/compound/orforglipron

The first small-molecule GLP-1 pill is approved — what Foundayo changes

When will orforglipron actually be available to fill at a pharmacy?

Track this in your own routine